FDA Approves Sunovion’s Kynmobi for Parkinson’s Disease

Sunovion Pharmaceuticals has received FDA approval for Kynmobi (apomorphine HCl) sublingual film for the treatment of Parkinson’s disease.

The approval is specifically for the acute, intermittent treatment of off episodes in Parkinson’s patients, which includes symptoms such as muscle stiffness, slow movements and difficulty starting movements.

Kynmobi is the first FDA-approved sublingual formulation of apomorphine, which is already approved as a subcutaneous injection for acute, intermittent treatment of off episodes in Parkinson’s patients.